ACR Convergence 2021

November 5-9, 2021. All Virtual.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 0897

Age-Stratified Trend of Spinal Radiographic Damage Progression in Patients with Ankylosing Spondylitis
Abstract Number: 0569

All-Cause and Cause-Specific Mortality in Spondyloarthritis: A Systematic Review and Meta-Analysis
Abstract Number: 1393

All-cause Mortality in a Hospital Ascertained Cohort with Giant Cell Arteritis: A Longitudinal Population-level Data Linkage Cohort Study
Abstract Number: 0306

Allergic Disorders in Primary Sjögren’s Syndrome Compared with Rheumatoid Arthritis
Abstract Number: 1429

ALPN-303, an Enhanced, Potent Dual BAFF/APRIL Antagonist Engineered by Directed Evolution for the Treatment of Systemic Lupus Erythematosus (SLE) and Other B Cell-Related Diseases
Abstract Number: 0065

Altered Expression of Several miRNAs in Axial Spondyloarthritis Patients with High Disease Activity
Abstract Number: 1092

Altered Metabolic Pathways in Synovial Fibroblasts of Individuals at Risk of Developing Rheumatoid Arthritis
Abstract Number: 1800

Altered Metabolic Profiles in the Transition from Psoriasis to Psoriatic Arthritis: A Longitudinal Analysis
Abstract Number: 0582

Altered Risk of Gout According to Change of Metabolic Parameters in Young Adults
Abstract Number: 1012

Altered T Cell Responses, and Synergistic Regulation of Synovial Fibroblasts Function in Children with Down’s Syndrome-Associated Arthritis
Abstract Number: 1464

Ambulatory Fetal Heart Rate Monitoring (FHRM) to Surveil Pregnancies at Risk for Congenital Heart Block
Abstract Number: 1759

An Analysis of Medication Responsiveness Based on Subtype and Race Within a Cohort of Cutaneous Lupus Erythematosus Patients
Abstract Number: 0472

An Atlas of Human and Mouse Intrarenal Immune Cells in Lupus Nephritis Reveals Homologous Immune Populations Across Common Mouse Strains and Species
Abstract Number: 0953

An International Delphi Exercise to Identify Items of Importance for Measuring Response to Treatment for ANCA-associated Vasculitis
Abstract Number: 0825

An Investigator-initiated Multicenter Randomized Study in Early Rheumatoid Arthritis of Active Conventional Therapy versus Three Biological Treatments: 48 Week Clinical and Radiographic Results of the NORD-STAR Trial

« Previous Page
1
…
6
7
8
9
10
…
132
Next Page »

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].